Immunovant, Inc. (IMVT) News
Follow Immunovant, Inc. (IMVT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: Cash to fund potential IMVT-1402 launch and 5% stock drop
Immunovant Inc (NASDAQ:IMVT) said cash fell to $797.8M on June 30 from $902.1M but should fund operations through a potential commercial launch of IMVT-1402 for Graves’ disease, while shares slid about 5% after results a
EQUITY | Sep 28, 2026, 11:06 AM UTC
L
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program — Barrons.com
By Mackenzie TatananniImmunovant shares were on track for their worst session in over a year after the biotech said it was halting development of its experimental autoimmune drug in one indication following a trial miss.
EQUITY | Sep 23, 2026, 05:45 PM UTC
L
Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint
By Chris WackImmunovant said it saw negative topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 imeroprubart for the treatment of cutaneous lupus erythematosus.The company said the study did
NEWS | Sep 23, 2026, 02:19 PM UTC
L
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Shares of Immunovant (IMVT) fell about 6% on Wednesday after its lead drug candidate failed to meet the primary goal of a proof-of-concept study in a form of lupus, prompting the company to stop developing the therapy fo
EQUITY | Sep 23, 2026, 12:33 PM UTC
L
Immunovant, Inc. (IMVT) Halts CLE Program After IMVT-1402 Misses Primary Endpoint
Immunovant said IMVT-1402 did not achieve statistical significance on the primary endpoint in its CLE proof-of-concept study and plans to stop development in CLE. Numerical trends favored IMVT-1402; other autoimmune indi
NEWS | Sep 23, 2026, 11:03 AM UTC
L
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Roivant NASDAQ:ROIV today announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 (imeroprubart)
NEWS | Sep 23, 2026, 11:03 AM UTC
L
IMVT - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
IMVT - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
NEWS | Sep 23, 2026, 11:01 AM UTC
H
Immunovant Q1 2027 Earnings Call: Complete Transcript
On Thursday, Immunovant (NASDAQ: IMVT ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our entir
LIVE | Sep 17, 2026, 12:18 PM UTC
L
IMVT - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
IMVT - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
EARNINGS | Aug 06, 2026, 11:01 AM UTC
L
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ: IMVT ) with a Buy and raises the price target from $57 to $61.
EQUITY | Jun 30, 2026, 06:49 PM UTC